ArticleCancer discovery2017
Targeting the Lysosome for Cancer Therapy.
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 76 citations in OpenAlex.
- Beyond the scaffold: extracellular matrix uptake in breast cancer.Biochemical Society transactions · 2026Review
- Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL).Blood advances · 2026Article
- Photothermal therapy triggering organelle stress and metabolic reprogramming to potentiate antitumor immunity.Frontiers in immunology · 2026Review
- Subcellular Organelle-Targeted Drug Delivery of Photodynamic Therapy and Gas-Photodynamic Combination Therapy.International journal of nanomedicine · 2025Review
- 3D DNAzyme Motor Nanodevice With Self-Powered FRET Amplifier and Self-Supplied HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives.Bioactive materials · 2024Review
- St-N, a novel alkaline derivative of stevioside, reverses docetaxel resistance by targeting lysosomes in vitro and in vivo.PloS one · 2024Article
- Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance.RSC chemical biology · 2023Review
- A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer.Acta pharmacologica Sinica · 2023Review
- Inhibition of proteasome, but not lysosome, upregulates organic anion transporter 3 in vitro and in vivo.Biochemical pharmacology · 2023Article
- Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis.Cancer communications (London, England) · 2023Article
- Trehalose Suppresses Lysosomal Anomalies in Supporting Cells of Oocytes and Maintains Female Fertility.Nutrients · 2022Article
- Review
- Review
- Autophagy Inhibition in BRAF-Driven Cancers.Cancers · 2021Review
- BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.Investigational new drugs · 2021Article
- Two Faces of Autophagy in the Struggle against Cancer.International journal of molecular sciences · 2021Review
- Lysosomal Calcium Channels in Autophagy and Cancer.Cancers · 2021Review
- Phosphorescent metal complexes as theranostic anticancer agents: combining imaging and therapy in a single molecule.Chemical science · 2021Review
- Endolysosomal TRPMLs in Cancer.Biomolecules · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
<b/> Lysosomes are the recycling centers of the cell where organelles and proteins are degraded during autophagy and macropinocytosis; they also serve as signaling hubs that control the activity of mTORC1. In this issue, Rebecca and colleagues report the development of a new type of lysosomal inhibitor for cancer therapy that can inhibit multiple lysosomal activities that are needed for tumor cell survival and growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.